Ceo and expert interviews

Botanix Pharmaceuticals (ASX:BOT) clinical trial update

16 Dec 2019 - Botanix Pharmaceuticals Limited (ASX:BOT) Founder Matthew Callahan talks about the company's Phase 2 US trial results for severe acne, plans for its Phase 3 trails, including FDA input, its Phase 2 atopic dermatitis study, and what investors can expect over the next 6 months.

Read more...

DomaCom (ASX:DCL) fractional investment platform

2 Dec 2019 - DomaCom Limited (ASX:DCL) CEO Arthur Naoumidis talks about a year of significant progress with regulators, the company's capital raising to accelerate marketing and FUM and the tailwinds making fractional investment attractive.

Read more...